[Special Stock] Nanos Highlights Exclusive Supply of Moderna mRNA-Loaded LNP Formulation Technology to CordenPharma

[Asia Economy Reporter Yoo Hyun-seok] Nanos is showing strong performance. The news that Moderna is establishing a branch in Korea seems to have influenced the technology partnership with Corden Pharma, which exclusively supplies LNP formulation technology.

As of 10:25 AM on the 28th, Nanos was trading at 7,120 KRW, up 6.43% (430 KRW) compared to the previous trading day.

According to the pharmaceutical industry, Moderna reportedly completed the registration for the establishment of 'Moderna Korea Co., Ltd.' at the Seoul Central District Court on the 17th.

As a result, Nanos, which signed a technology partnership agreement with Corden Pharma, the exclusive supplier of the core LNP formulation technology related to Moderna's mRNA vaccine, is drawing attention.

LNP technology (Lipid Nanoparticles) is an advanced formulation technology recently well known for being used in Moderna and Pfizer's 'mRNA' vaccines against COVID-19. This technology involves encapsulating mRNA fragments in nanoparticles and delivering them into the body, where the mRNA-coded vaccine proteins meet antibodies to create safe and highly efficient COVID-19 antibodies through a drug delivery system.

Germany-based Corden Pharma, which has a strategic technology partnership with Nanos, has been supplying lipid raw materials necessary for Moderna's mRNA product production since 2016, and it is estimated that its sales exceeded 500 million USD last year due to increased supply to Moderna.

This content was produced with the assistance of AI translation services.